CIK 1617201
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 60.97% | 31 |
| Health Care Equipment & Supplies | 18.20% | 8 |
| Unclassified | 9.37% | 2 |
| Health Care Providers & Services | 7.29% | 2 |
| Software | 2.49% | 1 |
| Commercial Services & Supplies | 1.67% | 2 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | NKTR | NEKTAR THERAPEUTICS | Health Care | 8.67% |
| 2 | BSX | BOSTON SCIENTIFIC CORP | Health Care | 8.19% |
| 3 | JANX | Janux Therapeutics, Inc. | Health Care | 8.09% |
| 4 | PRCT | PROCEPT BioRobotics Corp | Health Care | 7.98% |
| 5 | LKFT | GALAPAGOS NV | Unclassified | 7.63% |
| 6 | WGS | GeneDx Holdings Corp. | Health Care | 5.51% |
| 7 | STTK | Shattuck Labs, Inc. | Health Care | 5.28% |
| 8 | ADCT | ADC Therapeutics SA | Health Care | 5.10% |
| 9 | KURA | Kura Oncology, Inc. | Health Care | 4.48% |
| 10 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Health Care | 4.12% |
44/46 names classified · sector 90.6% of weight · industry 90.6% · mkt cap 88.7%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 90.6% of the book is sector-classified (unclassified names shown, never dropped).
Only 23% of book weight classified — the grid is NOT representative of the whole book.
Classified: 22.9% of book weight (10/46 names) · unclassified 77.1%: NKTR, JANX, PRCT, LKFT, WGS, STTK, ADCT, KURA, MGTX, SNDX +26 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | NKTRNEKTAR THERAPEUTICS | 735,000 | $53M | 8.7% | ADD 33% |
| 2 | BSXBOSTON SCIENTIFIC CORP | 795,547 | $50M | 8.2% | ADD 279% |
| 3 | JANXJANUX THERAPEUTICS INC | 3,550,000 | $49M | 8.1% | ADD 48% |
| 4 | PRCTPROCEPT BIOROBOTICS CORP | 1,945,000 | $49M | 8.0% | ADD 41% |
| 5 | LKFTGALAPAGOS NV | 1,550,000 | $47M | 7.6% | ADD 44% |
| 6 | WGSGENEDX HOLDINGS CORP | 523,463 | $34M | 5.5% | ADD 852% |
| 7 | STTKSHATTUCK LABS INC | 5,004,439 | $32M | 5.3% | ADD 110% |
| 8 | ADCTADC THERAPEUTICS SA | 8,300,000 | $31M | 5.1% | TRIM −2% |
| 9 | KURAKURA ONCOLOGY INC | 3,356,700 | $27M | 4.5% | ADD 33% |
| 10 | ALNYALNYLAM PHARMACEUTICALS INC | 76,000 | $25M | 4.1% | ADD 344% |
| 11 | MGTXMEIRAGTX HLDGS PLC | 2,629,971 | $23M | 3.7% | TRIM −18% |
| 12 | ALKSALKERMES PLC | 513,632 | $18M | 3.0% | NEW |
| 13 | SNDXSYNDAX PHARMACEUTICALS INC | 770,000 | $18M | 2.9% | ADD 16% |
| 14 | VEEVVEEVA SYS INC | 86,480 | $15M | 2.5% | TRIM −4% |
| 15 | ZYMEZYMEWORKS INC | 539,049 | $13M | 2.2% | HOLD |
| 16 | CRNXCRINETICS PHARMACEUTICALS IN | 350,000 | $13M | 2.1% | ADD 33% |
| 17 | ABVXABIVAX SA | 105,000 | $12M | 1.9% | ADD 518% |
| 18 | CONCONCENTRA GROUP HOLDINGS PAR | 505,822 | $11M | 1.8% | TRIM −43% |
| 19 | TERNS PHARMACEUTICALS INC | 202,300 | $11M | 1.7% | ADD 113% |
| 20 | PHRPHREESIA INC | 1,100,000 | $9M | 1.5% | ADD 13% |
| 21 | OKURONKURE THERAPEUTICS INC | 2,154,381 | $9M | 1.5% | ADD 164% |
| 22 | CRBPCORBUS PHARMACEUTICALS HLDGS | 697,108 | $7M | 1.1% | HOLD |
| 23 | SDGRSCHRODINGER INC | 510,578 | $6M | 1.0% | NEW |
| 24 | EBSEMERGENT BIOSOLUTIONS INC | 639,118 | $5M | 0.9% | NEW |
| 25 | ROIVROIVANT SCIENCES LTD | 180,000 | $5M | 0.8% | TRIM −71% |
| 26 | KIDSORTHOPEDIATRICS CORP | 302,399 | $5M | 0.8% | ADD 121% |
| 27 | IMVTIMMUNOVANT INC | 175,825 | $4M | 0.7% | TRIM −28% |
| 28 | ICUIICU MED INC | 27,450 | $4M | 0.6% | NEW |
| 29 | TECXTECTONIC THERAPEUTIC INC | 79,872 | $2M | 0.4% | TRIM −66% |
| 30 | RCKTROCKET PHARMACEUTICALS INC | 683,856 | $2M | 0.4% | TRIM −8% |
| 31 | UPBUPSTREAM BIO INC | 241,123 | $2M | 0.4% | NEW |
| 32 | PLRXPLIANT THERAPEUTICS INC | 1,667,600 | $2M | 0.3% | ADD 7% |
| 33 | OMEROMEROS CORP | 174,800 | $2M | 0.3% | NEW |
| 34 | ISRGINTUITIVE SURGICAL INC | 4,000 | $2M | 0.3% | NEW |
| 35 | ANTXAN2 THERAPEUTICS INC | 515,754 | $2M | 0.3% | NEW |
| 36 | ACETADICET BIO INC | 250,244 | $2M | 0.3% | HOLD |
| 37 | RGNXREGENXBIO INC | 200,000 | $2M | 0.3% | NEW |
| 38 | COYACOYA THERAPEUTICS INC | 420,360 | $2M | 0.3% | NEW |
| 39 | VKTXVIKING THERAPEUTICS INC | 45,000 | $1M | 0.2% | NEW |
| 40 | IRTCIRHYTHM HOLDINGS INC | 10,000 | $1M | 0.2% | NEW |
| 41 | TBITRUEBLUE INC | 249,107 | $974,008 | 0.2% | TRIM −44% |
| 42 | IMRXIMMUNEERING CORP | 123,409 | $650,365 | 0.1% | NEW |
| 43 | PVLAPALVELLA THERAPEUTICS INC | 5,000 | $623,250 | 0.1% | NEW |
| 44 | NVCRNOVOCURE LTD | 50,400 | $549,360 | 0.1% | NEW |
| 45 | RNTXREIN THERAPEUTICS INC | 411,600 | $535,080 | 0.1% | TRIM −7% |
| 46 | TMDXTRANSMEDICS GROUP INC | 5,000 | $497,050 | 0.1% | NEW |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| NKTRNEKTAR THERAPEUTICS | — | — | — | — | 555K | 735K | $53M |
| BSXBOSTON SCIENTIFIC CORP | — | — | — | 76K | 210K | 796K | $50M |
| JANXJANUX THERAPEUTICS INC | 330K | 690K | 854K | 865K | 2.4M | 3.5M | $49M |
| PRCTPROCEPT BIOROBOTICS CORP | — | — | — | 77K | 1.4M | 1.9M | $49M |
| LKFTGALAPAGOS NV | 1.0M | 1.3M | 1.8M | 1.1M | 1.1M | 1.6M | $47M |
| WGSGENEDX HOLDINGS CORP | — | — | — | — | 55K | 523K | $34M |
| STTKSHATTUCK LABS INC | 6.6M | 6.6M | 6.6M | 5.5M | 2.4M | 5.0M | $32M |
| ADCTADC THERAPEUTICS SA | 9.5M | 9.5M | 10.5M | 7.5M | 8.5M | 8.3M | $31M |
| KURAKURA ONCOLOGY INC | 1.3M | 2.1M | 3.2M | 2.8M | 2.5M | 3.4M | $27M |
| ALNYALNYLAM PHARMACEUTICALS INC | — | — | — | — | 17K | 76K | $25M |
| MGTXMEIRAGTX HLDGS PLC | 4.4M | 3.7M | 4.6M | 4.1M | 3.2M | 2.6M | $23M |
| ALKSALKERMES PLC | — | — | — | — | — | 514K | $18M |
| SNDXSYNDAX PHARMACEUTICALS INC | 620K | 609K | 1.1M | 1.0M | 665K | 770K | $18M |
| VEEVVEEVA SYS INC | — | — | — | — | 90K | 86K | $15M |
| ZYMEZYMEWORKS INC | 820K | 957K | 1.3M | 750K | 530K | 539K | $13M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
